Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Randomised, Parallel Group Study of the Drug-drug Pharmacokinetic Interaction of Steady State Tipranavir (SEDDS SEC) 500 mg and Ritonavir (Soft Gelatin Capsules) 100 mg or Tipranavir 750 mg and Ritonavir 200 mg, Both Bid for 13.5 Days With Single Dose Didanosine 400 mg (Delayed Release Capsule EC Beadlets) in Healthy Volunteers

NCT02251873 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02251873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02251873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Randomised, Parallel Group Study of the Drug-drug Pharmacokinetic Interaction of Steady State Tipranavir (SEDDS SEC) 500 mg and Ritonavir (Soft Gelatin Capsules) 100 mg or Tipranavir 750 mg and Ritonavir 200 mg, Both Bid for 13.5 Days With Single Dose Didanosine 400 mg (Delayed Release Capsule EC Beadlets) in Healthy Volunteers
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2001
Completion date
Not reported
Enrollment
50 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy